RISKS MITIGATED
The WAK has a clear path to market
LOW REGULATORY RISKS
Three successful clinical trials and fast-tracked by the FDA.
LOW REIMBURSEMENT RISKS
Dialysis reimbursement from CMS is guaranteed by law. The
escalatingcosts have driven CMS to look for innovation ASAP!
LOW TECHNOLOGY RISKS
Better performance data and R&D is further along than any competing technologies.
LOW INTELLECTUAL PROPERTY RISKS
Protected by families of patents for the WAK device
THE CLINICAL OPPORTUNITY
The Wearable Artificial Kidney is a RARE opportunity to invest in a pre-market technology that has limited barrier to approval
Regulatory Risks Mitigated: FDA/CMS
Want It Approved
Unmet medical Need With
Pent Up Demand
Technology Risk Mitigated by
Previous Successes
World Renowned Medical Team
THE FINANCIAL OPPORTUNITY
The Wearable Artificial Kidney is a RARE opportunity to invest in a pre-market technology that will transform an entire market
Only 2 remaining trials to FDA approval
INVESTOR CHECKLIST
Why you should have confidence investing in the WAK
SUFFICIENT TAM FOR A UNICORN SOLVES COMPELLING MEDICAL NEEDS A WORKING DEVICE HAS BEEN SUCCESSFUL COMMERCIAL DEVICE IS READY TO BUILD DEVICE IS PATENT PROTECTED FDA FAST-TRACKED APPROVAL WORLD CLASS TEAM LAUNCH & PROFITABILITY ARE NEAR-TERM A $B EXIT IS LIKELY WITHIN 3 – 4 YEARS CMS WILL REIMBURSE! Required by Law!